Phacilitate

  • About Us
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Events
  • Membership
    • Phacilitate Network
    • Advanced Therapies Investor Network
    • Women in Advanced Therapies
  • Latest News
Back
  • About Us
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Events
  • Membership
    • Phacilitate Network
    • Advanced Therapies Investor Network
    • Women in Advanced Therapies
  • Latest News
Join Today
Sign In
Sign In
Join Today
Industry Insights
Manufacturing
Techniques
Uncategorized
FDA Approves Kite’s Yescarta for Relapsed/Refractory Large B-cell Lymphoma

FDA Approves Kite’s Yescarta for Relapsed/Refractory Large B-cell Lymphoma

8 April 2022
FDA Approves Kite’s Yescarta for Relapsed/Refractory Large B-cell Lymphoma
The global biopharmaceutical company, Kite, a Gilead Company, has announced the FDA’s approval of their CAR-T cell therapy, Yescarta, for the treatment of adult patients with relapsed/refractory large B-cell lymphoma (LBCL).
Read More
Recent Stories
Castle Creek Bioscience Achieves $112.8 Million Financing to Advance Gene Therapies
26 May 2022
Castle Creek Bioscience Achieves $112.8 Million Financing to Advance Gene Therapies
The late-stage cell and gene
Umoja and Lupagen Collaboration Drives Improved Delivery for Next Generation <i data-src=
Virica Biotech Receives Funding from Canadian Government to Support the Re-Development of the Worlds First Ever Gene Therapy
18 May 2022
Virica Biotech Receives Funding from Canadian Government to Support the Re-Development of the Worlds First Ever Gene Therapy
Virica Biotech has announced collaboration
ASGCT: Highlights From the Program
16 May 2022
ASGCT: Highlights From the Program
Ryan Leahy summarizes what he’s
POPULAR NEWS ITEMS
Image
26 May 2022

Castle Creek Bioscience Achieves $112.8 Million Financing to Advance Gene Therapies

Image
25 May 2022

Key Takeaways from ASGCT 2022

Image
24 May 2022

Umoja and Lupagen Collaboration Drives Improved Delivery for Next Generation in vivo CAR-T

FDA and European Commission Both Grant Orphan Designation to AviadoBio’s Gene Therapy Product Targeting Frontotemporal Dementia
27 April 2022
FDA and European Commission Both Grant Orphan Designation to AviadoBio’s Gene Therapy Product Targeting Frontotemporal Dementia
AviadoBio has announced both the
FDA Grants Third RMAT Designation to AlloVir’s T Cell Therapy – Targeting Viruses in Allogeneic Hematopoietic Cell Transplant Patients
21 April 2022
FDA Grants Third RMAT Designation to AlloVir’s T Cell Therapy – Targeting Viruses in Allogeneic Hematopoietic Cell Transplant Patients
AlloVir, has announced the FDA
Load More News
RECOMENDED TOPICS
CAR-X
Cell Therapy
Collaborations, Mergers & Acquisitions
Partnering
Finance & Investment
Gene Therapy
GMP
Manufacturing
Scaling Up
Gene Editing
Skills, Talent & Development
Viral/Non-Viral Vectors
Regulatory & Standards
Allogeneic
Clinical Trials
Cell-Based IO
Industry Insights
Patient Access & Engagement
Supply Chain
CMC
Automation & Digitisation
Logistics
Stem Cells
Tissue Engineering
NKx
Point of Care
Reimbursement
Uncategorized
POPULAR NEWS ITEMS
Image

Castle Creek Bioscience Achieves $112.8 Million Financing to Advance Gene Therapies

Image

How Collaboration and Simplification is Key to Solving Industry-Wide Efficacy and Supply Chain Challenges

Image

Key Takeaways from ASGCT 2022

logo_footer
logo_mobile_footer
Company
  • About Us
  • Events
  • Contact Us
Resources
  • Insights and Resources
  • Latest News
  • Phacilitate Podcast
  • Content Services
Network
  • Sign In
  • Join Today
social_icon Linkedin
social_icon Twitter

Clarion Events Limited is registered in England and Wales, Company Number 00454826, VAT No. GB 843845601 Registered Office: Bedford House, 69-79 Fulham High Street, London, SW6 3JW, United Kingdom.

  • Privacy Policy
  • Code of Conduct
  • Terms & Conditions
  • Cookies
Phacilitate is a part of Clarion Events Limited. © Phacilitate 2022